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Abstract
Background: Emerging data suggests that the combination of smoking and metabolic syndrome (MetS)
markedly increases cardiovascular disease risk well beyond that of either condition. In this study we assess if this
interaction can be explained by an additive increase in the risk of systemic inflammation by MetS and cigarette
smoking.
Methods: We evaluated 5,503 healthy non-diabetic Brazilian subjects (mean age of 43 ± 10 years, 79% males).
Participants were divided into sub-groups of smokers and non-smokers with or without MetS. High-sensitivity C
reactive protein (hs-CRP) was measured to assess degree of underlying inflammation.
Results: Overall (19%) had hs-CRP > 3 mg/L. In adjusted regression analyses, compared to non-smokers, there was a
0.19 mg/L (95% CI: 0.05, 0.32) increase in hs-CRP among smokers in the entire population and 0.63 mg/L (95% CI:
0.26, 1.01) increase among smokers with MetS while there was no significant increase among smokers without MetS
(β = 0.09 95% CI: −0.05, 0.24). In a fully adjusted logistic regression model, smokers compared to non-smokers were
55% more likely to have elevated hs-CRP in the entire population (OR 1.55, 95% CI: 1.25, 1.92) and more than twice
as likely to have elevated hs-CRP if they had MetS ( OR 2.05, 95% CI: 1.40, 3.01) while the risk was non-significant
among those without MetS (OR = 1.29, 95% CI: 0.98, 1.69).
Conclusion: The study demonstrates an additive effect of cigarette smoking on the risk of systemic inflammation in
MetS thus highlighting the need for determining smoking status among those with MetS and aggressively
targeting smoking cessation in this population.
Keywords: Cigarette smoking, Metabolic syndrome, Systemic inflammation, High sensitivity C-reactive protein,
Cardiovascular disease risk
Introduction
Cigarette smoking and metabolic syndrome (MetS) are
both well established cardiovascular disease (CVD) risk
factors. With an estimated 44 million adult smokers in the
United States (US) or 19% of all US adults, the health-care
burden of CVD attributable to smoking is remarkable,
accounting for about one-third of all CVD related deaths
[1]. Globally, cigarette smoking is responsible for about
10% of all CVDs [2]. In the US, about 1 in 5 persons can
be categorized as having MetS, a major public health
problem likely driven by the increasing prevalence of
obesity [3]. MetS is also a global health issue and is likely
to persist with increasing prevalence of obesity [4,5].
Several studies have linked cigarette smoking to the
presence and progression of atherosclerosis [6,7], and to
markers of systemic inflammation including high-sensi-
tivity C - Reactive Protein (hs-CRP) [8-10]. MetS is
also associated with increased risk of CVD morbidity
and mortality, and with all cause mortality [11]. Similar
to cigarette smoking, both obesity and the MetS are
associated with systemic inflammation [12]. Population
studies have shown an association between cigarette
smoking and the presence of MetS, and there is increasing
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evidence that cigarette smoking increases the risk for
MetS [13-15].
Recent studies have examined the interrelationship
between cigarette smoking and MetS on CVD risk
[16,17]. One of these studies demonstrated a synergistic
effect of cigarette smoking and MetS on CVD risk [16].
Both MetS and smoking may mediate CVD risk through
shared mechanisms. Each induce systemic inflammation
and the increased risk of CVD in smokers with MetS
may be due, in part, to increased systemic inflammation
in persons with both conditions. Though logical, there
is limited evidence to support this assertion. We, there-
fore, tested the hypothesis that among persons with
MetS, cigarette smoking worsened the risk of systemic
inflammation.
Methods
Study population and design
This cross-sectional study was conducted in a popula-
tion that consisted of 5,503 asymptomatic males and
females, free from known diabetes and coronary heart
disease, who presented to the Preventive Medicine Cen-
ter of Albert Einstein Hospital in São Paulo, Brazil, for
clinical and laboratory investigations as part of a
mandatory occupational health evaluation. Each partici-
pant had clinical consultation including a history and
physical examination, laboratory examination and ab-
dominal ultrasound scanning as part of their evaluation.
Information collected included demographic details,
self-reported history of medical conditions such as
hypertension and diabetes mellitus, use of medication
including antihypertensives, antidiabetics and statins,
alcohol use, and a self reported history of current
cigarette smoking.
Materials and methods
Anthropometric measurements such as weight (in kilo-
grams), height (in meters) and waist circumference (mea-
sured at the smallest diameter between the iliac crest and
the costal margin in centimeters) were obtained. Body mass
index was calculated using the formula BMI = weight/
(height)2. Blood pressure (BP) was measured using a cali-
brated aneroid sphygmomanometer after at least 5 minutes
rest and according to guidelines from the American Heart
Association [18].
Fasting blood samples were obtained for plasma lipids
including high density lipoprotein cholesterol (HDL-c),
low density lipoprotein cholesterol (LDL-c), triglycerides
(TG), blood glucose and hs-CRP. hs-CRP levels were
determined by immunonephelometry (Dade-Behring). The
previously established cut-off point of >3 mg/L, a level as-
sociated with increased CVD risk in prospective studies
[19] was used to define elevated hs-CRP. All tests were
performed at the central laboratory of the Albert Einstein
Hospital.
We defined MetS using the International Diabetes
Federation criteria. This includes central obesity (waist
circumference ≥ 94 cm in men or ≥80 cm in women)
and any two of the following factors – hypertension, ele-
vated triglyceride levels, reduced HDL-c, or elevated fast-
ing glucose [20]. Smokers were defined as those who had
reported smoking at least one stick of cigarette in the
month prior to the evaluation while non-smokers were
those who did not report smoking any cigarettes in the
previous month. Based on the presence of MetS and
cigarette smoking, participants were categorized into 4
groups namely - non-smokers without MetS, smokers
without MetS, non-smokers with MetS and smokers with
MetS. This study was approved by the local IRB and a
waiver for informed consent was obtained.
Statistical analysis
Continuous variables including hs-CRP were examined
graphically for normality and are presented as mean ± SD
or median (IQR). Categorical variables are expressed as
percentages. Student t-tests were used to compare the
means of continuous variables between smoking groups
(smokers versus non-smokers) while chi-square test of
independence was used to compare the frequencies of
categorical variables between these two smoking groups.
For comparisons of median values of hs-CRP between
smokers and non-smokers the wilcoxon rank-sum test
was employed.
Median hs-CRP levels as well as their interquartile
ranges (IQRs) are presented for each MetS and cigarette
smoking category. Similarly, the prevalence of hs-CRP for
each of these groups is also graphically presented. We
conducted both median linear regression and logistic re-
gression analysis for the effect of smoking on hs-CRP, with
hs-CRP expressed as continuous and categorical (hs-CRP
>3 mg/L) variables respectively. We chose median linear
regression because hs-CRP was non-parametrically dis-
tributed. Sub-group analyses were conducted for groups
with and without MetS. Interaction terms were created
and p-values generated. We conducted additional regres-
sion analyses assessing the effect of smoking and MetS
individually and together on hs-CRP using the four
subject groups described above, with non-smokers
free of MetS as the reference group. Finally we conducted
similar analysis in sub-groups based on their number of
MetS components (elevated waist circumference, triglyc-
erides, blood pressure and glucose, and low HDL-c as
earlier mentioned). For each regression analysis univariate
and multivariate analysis were conducted adjusting for
age, sex, LDL-c, total cholesterol, statin use and anti-
hypertensive therapy. Because the definition of MetS
included hypertension, dyslipidemia and surrogates for
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obesity (waist circumference), they were excluded from
our models. A p value ≤0.05 was considered statistically
significant. All analysis was conducted in STATA version
12 (StataCorp. 2011. Stata Statistical Software: Release 12.
College Station, TX: StataCorp LP).
Results
General characteristics
The study population consisted of 5,503 participants.
The mean age of the population was 43.1 ± 9.4 years and
about 78% of them were male. Approximately 9% (498)
were self-reported current smokers while the prevalence
of MetS was 20%. About 19% of the population had
elevated hs-CRP (>3.0 mg/L). The median (IQR) hs-CRP
in the entire population was 1.2 mg/L (0.6-1.4 mg/L)
and was significantly higher in smokers than in non-
smokers (1.40 mg/L vs. 1.20 mg/L p < 0.001). Among the
smokers, 26% had elevated hs-CRP compared to about
19% among the non-smokers (p < 0.001). Other details
of the general characteristics are available in Table 1.
Relationship between smoking and MetS
The prevalence of MetS was significantly greater among
smokers than non-smokers (26.5% vs. 19.8% p < 0.001).
In logistic regression analysis before and after control-
ling for age and sex, antihypertensive and antidiabetic
medications and total cholesterol, the odds of MetS
was 46% and 36% greater among smokers compared
to non-smokers (Unadjusted OR 1.46 95% CI: 1.18,
1.81 p <0.001; Adjusted OR 1.36 95% CI: 1.08, 1.72
p = 0.008).
Relationship between smoking and hs-CRP among
persons with and without metabolic syndrome
Among those without MetS, there was no significant dif-
ference in the median hs-CRP between smokers and non-
smokers (p = 0.11) however, among those with MetS, the
median hs-CRP was significantly higher in smokers
(2.4 mg/L, IQR 1.2-4.8 mg/L) than in non-smokers
(1.8 mg/L, IQR 1.0-3.1 mg/L) (p = 0.002; Figure 1). In the
unadjusted linear regression analysis comparing smokers
to non-smokers, smoking was associated with a 0.20 mg/L
(95% CI: 0.07, 0.33) increase in median hs-CRP in the
entire population and 0.60 mg/L (95% CI: 0.10, 1.01)
increase in hs-CRP among those with MetS (Table 2).
However, among those without MetS, smoking had no ef-
fect on hs-CRP (regression coefficient 0.10, 95% CI: −0.04,
0.24). Similar associations were found in the fully adjusted
model. In addition, there was significant interaction
between MetS and smoking in univariate (p = 0.002)
and both multivariate analyses (p = 0.001) (Table 2).
In the group without MetS, there was no significant dif-
ference in the prevalence of elevated hs-CRP among
smokers versus non-smokers (20% vs. 17% p = 0.08)
Table 1 Population characteristics grouped according to smoking status
Variable All participants (N = 5503) Non-Smokers (±SD) (N = 5,005) Smokers (±SD) (N = 498) p-value
Mean age (years) 43.48 ± 9.53 43.45 ± 9.48 43.76 ± 9.98 0.453
Male sex (%) 78.79 78.69 79.83 0.526
Mean waist circumference (cm) 91.59 ± 12.02 91.51 ± 12.02 92.40 ± 12.04 0.089
BMI (Kg/m2) 26.32 ± 3.99 26.30 ± 4.00 26.58 ± 3.72 0.100
Metabolic syndrome (%) 20.09 19.54 25.91 <0.001
Mean Uric acid (mg/dL) 5.80 ± 1.40 5.80 ± 1.40 5.90 ± 1.38 0.171
Mean HDL-c (mg/dL) 48.27 ± 13.06 48.48 ± 13.09 46.20 ± 12.58 <0.001
Mean triglyceride (mg/dL) 136.65 ± 86.69 133.87 ± 81.48 164.90 ± 122.51 <0.001
Mean LDL-c (mg/dL) 130.74 ± 33.25 130.65 ± 33.09 131.82 ± 34.83 0.423
Mean total cholesterol (mg/dL) 205.94 ± 37.12 205.60 ± 36.81 209.69 ± 39.92 0.012
On statins (%) 8.65 8.49 10.26 0.150
With hepatic steatosis (%) 36.18 35.57 42.38 0.001
Mean fasting glucose (%) 89.30 ± 10.26 89.27 ± 10.34 89.49 ± 10.63 0.624
Mean SBP (mmHg) ± SD 118.8 ± 12.7 118.7 ± 12.8 119.8 ± 12.5 0.065
Mean DBP (mmHg) ± SD 76.9 ± 8.1 76.9 ± 8.1 77.3 ± 8.1 0.295
Hypertension (%) 21.24 12.61 13.22 0.394
On anti-hypertensive medications (%) 12.27 12.24 12.7 0.749
Median hs-CRP (IQR) (mg/L) 1.2 (0.6-2.40) 1.20 (0.60-2.40) 1.40 (0.70-3.00) <0.001
% Elevated hs-CRP (>3.0 mg/L) 19.24 18.60 26.10 <0.001
SD: standard deviation; BMI: body mass index; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol; and hs-CRP: high sensitivity
C-reactive protein.
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however among those with MetS the hs-CRP prevalence
was 42.4% among smokers compared to 26.8% among
non-smokers (p < 0.001).These results are depicted in
Figure 2. In a fully adjusted logistic regression model,
cigarette smoking was associated with a 55% increase in the
odds of elevated hs-CRP in the entire population (OR 1.55,
95% CI: 1.25, 1.92) and more than double the odds of ele-
vated hs-CRP among those with MetS (OR 2.05, 95% CI:
1.40, 3.01). However, there was no significant effect of
smoking on hs-CRP in the population without MetS (OR
1.29, 95% CI: 0.98, 1.69). Again, there was significant
interaction between MetS and smoking on hs-CRP in
unadjusted (p = 0.049) and the age and sex adjusted
models (p interaction = 0.05) but not in the fully adjusted
model (p interaction = 0.076). Details of the results of the
logistic regression analysis are shown in Table 2.
Comparison of hs-CRP among non-smokers without Mets
to smokers with MetS, smokers without MetS and
non-smokers with MetS
There was a stepwise increase in the median hs-CRP
and the prevalence of elevated hs-CRP in the following
order: non-smokers without MetS, smokers without
MetS, non-smokers with MetS and smokers with MetS
(Figures 1 and 2). In adjusted regression analysis hs-CRP
was 1.3 mg/L (95% CI: 1.0, 1.6) and 0.7 mg/L (95% CI:
0
2
4
6
8
1
0
MetS (-) MetS (+)
Non-Smoker Smoker Non-Smoker Smoker
*excludes outside values
P= 0.112
P= 0.002
Figure 1 Box plots comparing median and interquartile ranges of hs-CRP between smokers and non-smokers in populations with and
without metabolic syndrome (MetS).
Table 2 Linear and logistic regression analyses for the effect of cigarette smoking on Hs-CRP and interaction with
metabolic syndrome
Median linear regression coefficients (95% CI)
Total MetS absent MetS present P interaction
Model 1 0.20 (0.07, 0.33) 0.10(−0.04, 0.24) 0.60 (0.23, 0.97) 0.002
Model 2 0.18 (0.04, 0.32) 0.11 (−0.04, 0.26) 0.60 (0.10, 1.01) 0.001
Model 3 0.19 (0.05, 0.32) 0.09 (−0.05, 0.24) 0.63 (0.26, 1.01) 0.001
Logistic regression odds ratio for elevated hs-CRP (95% CI)
Total MetS absent MetS present P interaction
Model 1 1.54 (1.25, 1.91) 1.27 (0.97, 1.66) 2.02 (1.39, 2.93) 0.049
Model 2 1.55 (1.26, 1.93) 1.28 (0.97, 1.67) 2.05 (1.40, 2.99) 0.05
Model 3 1.55 (1.25, 1.92) 1.29 (0.98, 1.69) 2.05 (1.40, 3.01) 0.076
Model 1: unadjusted; Model 2: adjusted for age and sex; and Model 3: adjusted for age, sex, LDL, total cholesterol, statins and anti-hypertensive medications
hs-CRP: high sensitivity C-reactive protein; and MetS: metabolic syndrome elevated hs-CRP = hs-CRP >3 mg/L.
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0.6, 0.8) higher among smokers with MetS and non-
smokers with MetS compared to non-smokers without
MetS. However, there was no significant increase in hs-
CRP associated with smokers without MetS compared
with non-smokers without MetS (β = 0.11 95% CI: −0.1,
0.3). Again, compared with non-smokers without MetS,
smokers with MetS and non-smokers with Mets were 4
times and 2 times more likely to have elevated hs-CRP
while the risk was not significantly elevated for those who
smoke but do not have MetS (OR 1.30 95% CI: 1.0, 1.7).
Details can be found in Table 3.
Discussion
In this study population, smoking was associated with
prevalent MetS and in those who had MetS, smoking
more than doubled the risk of systemic inflammation.
The combination of smoking and MetS was also associ-
ated with a four-fold increase in the likelihood of systemic
inflammation when compared to non-smokers without
MetS. Interestingly, smokers without MetS did not have
elevated risk of systemic inflammation. Taken together,
our results imply that smoking significantly and adversely
modifies the effect of MetS on systemic inflammation,
supporting our earlier hypothesis that smoking worsens
Figure 2 Prevalence of elevated hs-CRP among smokers compared to non-smokers in populations with and without metabolic syndrome.
Table 3 Linear and logistic regression analyses for the
combined effect of cigarette smoking and metabolic
syndrome on hs-CRP
Median linear regression coefficients (95% CI)
Smokers with
no MetS
Non-smokers
with MetS
Smokers with
MetS
Model 1 0.10 (−0.06, 0.26) 0.70 (0.60, 0.80) 1.3 (1.06, 1.56)
Model 2 0.12 (−0.04, 0.29) 0.73 (0.62, 0.84) 1.39 (1.13, 1.66)
Model 3 0.11 (−0.05, 0.27) 0.69 (0.58, 0.79) 1.29 (1.03, 1.55)
Logistic regression odds ratio for elevated hs-CRP (95% CI)
Smokers with
no MetS
Non-smokers
with MetS
Smokers
with MetS
Model 1 1.27 (0.97, 1.66) 1.83 (1.56, 2.16) 3.70 (2.59, 5.28)
Model 2 1.28 (0.97, 1.67) 2.09 (1.76, 2.48) 4.24 (2.95, 6.08)
Model 3 1.30 (0.99, 1.71) 2.02 (1.69, 2.41) 4.00 (2.77, 5.08)
Model 1: unadjusted; Model 2: adjusted for age and sex; and Model 3:
adjusted for age, sex, LDL, total cholesterol, statins and anti-hypertensive
medications Hs-CRP: high sensitivity C-reactive protein; and MetS:
metabolic syndrome elevated hs-CRP = hs-CRP >3 mg/L.
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the systemic inflammation among persons with MetS. We
were however surprised that there was no significant effect
of smoking on systemic inflammation among persons who
did not have MetS.
Several studies have demonstrated an association
between smoking and MetS and this association has
been summarized in a recent review and meta-analysis
[15]. Smoking has a well documented, independent, dose–
response relationship with systemic inflammation as mea-
sured by hs-CRP [21-23]. Consistent with prior reports, in
the present study smoking was associated with both MetS
and systemic inflammation. One of the arguments behind
the development of MetS in smokers is the induction of
insulin resistance [24-26], the major driver of the MetS.
Our study shows that cigarette smoking further escalates
systemic inflammation in persons with MetS, as shown by
an additional increase of 0.6 mg/L in the level of hs-CRP
and a 100% increase in the risk of elevated hs-CRP
(>3 mg/L). Elevated hs-CRP has been closely linked with
the development of atherosclerosis and is associated with
the development of and mortality from CVD [27]. Though
not proven here, our study suggests that aggravation of
systemic inflammation by cigarette smoking may account
for the increased risk of CVD in cigarette smokers with
MetS.
The major strength of our study is that it was carried
out in a large cohort of over 5,500 individuals free of
known CVD and with information regarding import-
ant covariates. The analysis is also unique as it is one
of the earliest to demonstrate an additive effect of
cigarette smoking on the risk of systemic inflammation in
persons with MetS. However, we are limited by several
factors. The cross-sectional design precludes defining the
temporal relationship between smoking and hs-CRP. The
study population comprised mainly of men mostly in their
forties and free of CVD. Therefore, the findings cannot be
generalized to women or populations in a different age
bracket. The fact that most of the covariates, including the
primary exposure – cigarette smoking is self-reported
opens up the possibility of misclassification of exposure
and the potential for a misclassification bias. Smokers
were not classified as never smokers or non smokers,
which would have reduced the bias of “sick quitter effect”.
In addition, no measure of smoking burden was taken into
account, all of which may have affected our results and
may account for lack of a significant difference in hs-CRP
among those without MetS.
Implications and conclusions
Both smoking and MetS are among the leading causes of
preventable CVD related deaths in the US and globally.
Although the prevalence of smoking and other traditional
CVD risk factors (dyslipidemia and hypertension) in the
US has decreased from 1960 to 2000, the same period has
seen a dramatic rise in the prevalence of obesity and MetS
[1,28]. Despite the decline in smoking rates, 19% of the
US population are smokers and cigarette smoking still
accounts for over 400,000 deaths yearly in the US,
32% of which are CVD related [1,29]. Globally, tobacco
use accounts for about 10% of all CVD related mortality,
with the highest occurrences being in low to mid-income
countries [2]. Yet awareness about the cardiovascular
implications of cigarette smoking are still unaccept-
ably low considering that smoking is a completely
preventable cause of CVD [2].
From the results of this study, the absence of smoking,
even in the presence of MetS is associated with a 50%
reduction in risk of systemic inflammation. Other
studies have demonstrated that smoking cessation sub-
stantially reduces CVD risk [30]. This study also empha-
sizes the importance of assessing smokers for metabolic
abnormalities and establishing smoking status in those
who present with features of the MetS. Smoking ces-
sation attempts need to be more rigorous in those
with MetS. There is strong argument that smoking
cessation may benefit smokers with MetS [17] since
smoking cessation improves insulin sensitivity [31] and
could break the interaction between the two.
Our study, as well as others, underscores the need for
active pursuant of smoking cessation in the general popu-
lation by modifying smoking related public health policies
and intensive interventions in clinical practice especially
among those who have metabolic abnormalities or MetS.
Moreover, further studies are needed to understand the
processes responsible for the additive effect of smoking
and MetS on inflammation.
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